Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin’s Lymphoma: The Predictive Role of the Largest and the Hottest Lesions
暂无分享,去创建一个
L. Nardo | S. Hohaus | M. Mayerhoefer | L. Boldrini | R. Gatta | E. K. Triumbari | S. Annunziata | E. Maiolo | D. Morland | Marco De Summa
[1] S. Hohaus,et al. Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment , 2022, Diagnostics.
[2] L. Boldrini,et al. Radiomics in Oncological PET Imaging: A Systematic Review—Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers , 2022, Diagnostics.
[3] G. Perini,et al. Baseline total metabolic tumor volume (TMTV) application in Hodgkin lymphoma: a review article , 2022, Clinical and Translational Imaging.
[4] R. Boellaard,et al. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma , 2022, The Journal of Nuclear Medicine.
[5] M. Mayerhoefer,et al. The role of 18F-FDG PET/CT radiomics in lymphoma , 2021, Clinical and Translational Imaging.
[6] R. Boellaard,et al. Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? , 2021, The Journal of Nuclear Medicine.
[7] R. Flavell,et al. Treatment of sarcoidosis with cutaneous involvement with tofacitinib , 2021, medRxiv.
[8] Alejandro F Frangi,et al. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[9] J. Yahalom,et al. The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT , 2021, Leukemia & lymphoma.
[10] O. Alonso,et al. Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma. , 2020, Nuclear medicine communications.
[11] H. H. El-Bahnasawy,et al. Correlation of texture feature analysis with bone marrow infiltration in initial staging of patients with lymphoma using 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography , 2020, Polish journal of radiology.
[12] Xuejun Ma,et al. Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma , 2020, Medicine.
[13] Y. Balagurunathan,et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.
[14] R. Advani,et al. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] Xuelei Ma,et al. Current status and quality of radiomics studies in lymphoma: a systematic review , 2020, European Radiology.
[16] S. Ansell. Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management , 2020, American journal of hematology.
[17] C. Nanni,et al. Methodological framework for radiomics applications in Hodgkin’s lymphoma , 2020, European Journal of Hybrid Imaging.
[18] Mauro Iori,et al. Texture analysis and multiple-instance learning for the classification of malignant lymphomas , 2020, Comput. Methods Programs Biomed..
[19] S. Q. Brunetto,et al. Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma , 2020, The Journal of Nuclear Medicine Technology.
[20] Georg Langs,et al. Introduction to Radiomics , 2020, The Journal of Nuclear Medicine.
[21] K. Chuang,et al. Intratumor Heterogeneity Assessed by 18F-FDG PET/CT Predicts Treatment Response and Survival Outcomes in Patients with Hodgkin Lymphoma. , 2019, Academic radiology.
[22] K. Chuang,et al. Prognostic Value of Pretreatment Radiomic Features of 18F-FDG PET in Patients With Hodgkin Lymphoma. , 2019, Clinical nuclear medicine.
[23] Alex Zwanenburg,et al. Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[24] J. Zaucha,et al. The role of PET/CT in the modern treatment of Hodgkin lymphoma. , 2019, Cancer treatment reviews.
[25] T. Watabe,et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma , 2019, International Journal of Clinical Oncology.
[26] C. Fuller,et al. A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma , 2019, Scientific Reports.
[27] R. Advani,et al. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. , 2018, Hematology. American Society of Hematology. Education Program.
[28] M. Federico,et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] A. Nelson,et al. Evaluation of a semi-automated whole body PET segmentation method applied to Diffuse Large B Cell Lymphoma , 2018 .
[30] L. Cozzi,et al. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[31] Steve Y. Cho,et al. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? , 2018, Nuclear Medicine and Molecular Imaging.
[32] D. Mariano-Goulart,et al. Association between textural and morphological tumor indices on baseline PET‐CT and early metabolic response on interim PET‐CT in bulky malignant lymphomas , 2017, Medical physics.
[33] Stefan Leger,et al. Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.
[34] A. Afaq,et al. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin’s and aggressive non-hodgkin’s lymphomas , 2016, European Radiology.
[35] S. Hohaus,et al. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET) , 2016, Annals of Nuclear Medicine.
[36] Mauro Vallati,et al. Moddicom: a complete and easily accessible library for prognostic evaluations relying on image features , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[37] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[38] R. Fisher,et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Carole Lartizien,et al. Computer-Aided Staging of Lymphoma Patients With FDG PET/CT Imaging Based on Textural Information , 2012, IEEE Journal of Biomedical and Health Informatics.
[41] Rathan M. Subramaniam,et al. 18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging , 2012, The Journal of Nuclear Medicine.
[42] Kristin D. Brockway,et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. , 2012, International journal of radiation oncology, biology, physics.
[43] J. Radford,et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[44] V. Diehl,et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[46] Yan Liu,et al. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants , 2014, Medical Oncology.
[47] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[48] V. Grégoire,et al. Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.